FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
MWN-AI** Summary
FibroBiologics, Inc. (Nasdaq: FBLG), a Houston-based clinical-stage biotechnology company specializing in fibroblast technology, has announced the completion of site onboarding for its Phase 1/2 clinical trial of CYWC628, a promising treatment for refractory diabetic foot ulcers (DFUs). This multicenter, open-label trial aims to evaluate the safety, tolerability, and efficacy of CYWC628—a topically administered allogeneic fibroblast spheroid therapy. Participants will receive standard of care combined with varying doses of CYWC628 or standard treatment alone for up to 12 weeks.
An interim analysis will be conducted after a specified number of participants complete the initial six weeks of treatment to assess primary safety and efficacy endpoints. This analysis is crucial as it will provide insights into the potential of CYWC628 in enhancing wound healing among patients with DFUs, a condition that can lead to serious complications and significantly impact quality of life.
Hamid Khoja, Chief Scientific Officer, emphasized the importance of this clinical trial in demonstrating the capabilities of fibroblast spheroid therapies. The collaboration with Southern Star Research, an Australian clinical research organization, will aid in the execution of this complex early-phase trial, leveraging their expertise to ensure high-quality data generation.
FibroBiologics, which holds over 270 patents in various clinical pathways, is committed to advancing innovative therapies for chronic diseases. The successful initiation of this clinical trial marks a significant step in the company's goal to position fibroblast-derived materials as a transformative treatment option in the field of chronic wound care.
As FibroBiologics prepares for the next phase of this trial, the biotech community and investors will be keenly observing the outcomes that may redefine treatment protocols for refractory diabetic foot ulcers.
MWN-AI** Analysis
FibroBiologics, Inc. (Nasdaq: FBLG) has recently completed site onboarding for its Phase 1/2 clinical trial investigating CYWC628, an innovative therapy aimed at treating refractory diabetic foot ulcers (DFUs). This pivotal step signifies a critical phase in the drug development process and could hold substantial implications for both the company and investors.
The clinical trial, focusing on the efficacy and safety of CYWC628, marks FibroBiologics' commitment to advanced wound care solutions. The primary goal is to compare the outcomes of the therapy (administered at varying doses alongside standard care) against standard care alone over a 12-week period. The involvement of Southern Star Research, a reputable clinical research organization, enhances the credibility of the trial and suggests a robust management plan in place for data collection and analysis.
Market-wise, the success of the trial could position FibroBiologics favorably in the crowded biotech landscape, especially given the increasing prevalence of diabetic foot ulcers in an aging population. If CYWC628 demonstrates meaningful efficacy, it could capture market share from existing treatments, potentially translating into significant revenue streams for the company.
However, potential investors should tread carefully due to the inherent risks associated with clinical trials. The reliance on forward-looking statements highlights the uncertainty surrounding trial outcomes and the company's future performance. The data generated will be crucial; an interim analysis after six weeks could provide early insights into the therapy's viability, positively influencing market sentiment if results are favorable.
In conclusion, FibroBiologics presents an intriguing opportunity for growth, contingent on the successful execution of its clinical trial strategy. Investors should closely monitor interim results and broader market trends in biotherapeutics related to chronic wound care to make informed decisions about potential investment in FBLG.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that onboarding of the clinical sites has been completed for its Phase 1/2 clinical trial evaluating the safety and efficacy of CYWC628 for the treatment of refractory diabetic foot ulcers (DFUs).
The clinical trial is a prospective, multicenter, open label study designed to evaluate the safety, tolerability, and efficacy of FibroBiologics’ investigational topically administered allogeneic fibroblast spheroid-based therapy, CYWC628, for the treatment of refractory DFUs. Participants will receive up to 12 weeks of treatment using either standard of care (SoC) plus a low or high dose of CYWC628, or SoC alone. FibroBiologics has completed site onboarding as outlined in the protocol for the clinical trial but will activate additional sites if needed to support recruitment objectives.
“This clinical trial will assess wound healing outcomes, durability of response, and safety parameters through regular clinical observation, testing, and imaging evaluations. An interim analysis will be conducted after a predefined number of participants complete six weeks of treatment to assess primary safety and efficacy endpoints,” said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics.
“Successfully engaging all clinical trial sites is a critical step as we advance towards trial initiation to demonstrate the potential of fibroblast spheroid-based therapies as a major breakthrough in DFU treatment,” said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics. “With site onboarding complete, our human trial partners are in place and we are now focused on disciplined execution. We look forward to generating data that can clearly inform how this therapy fits into the future of chronic wound care.”
Southern Star Research, a leading full-service Australian CRO with APAC coverage, is managing all aspects of the CYWC628 trial from start to finish. “The CYWC628 program is an excellent fit for Australia’s ecosystem and Southern Star Research’s expertise in complex early-phase trials. We look forward to generating high-quality data to support FibroBiologics’ innovative fibroblast spheroid therapy for patients with refractory diabetic foot ulcers,” said Lloyd Prescott, CEO of Southern Star Research.
For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the anticipated timing of the initiation of and results from, FibroBiologics’ clinical trials, and the potential clinical benefits of fibroblasts and fibroblast-derived materials, including being a major breakthrough in DFU treatment. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) the unpredictable relationship between R&D and preclinical results and clinical study results; (c) the ability of FibroBiologics to successfully prosecute its patent applications, (d) FibroBiologics’ ability to manufacture its product candidates; and (e) FibroBiologics’ ability to conduct clinical trials. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About CYWC628
CYWC628 is an investigational topically administered allogeneic fibroblast cell-based therapy for wound healing. Preclinical data suggest CYWC628 may significantly accelerate wound healing compared to currently available treatments.
FibroBiologics is planning a prospective, multicenter, open-label clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to 12 weeks of treatment using either standard of care plus a low or high-dose of CYWC628, or standard of care only.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
About Southern Star Research
Southern Star Research is a full-service clinical research organization headquartered in Australia, guiding small and mid-sized biotech, pharmaceutical, and medical device companies to confidently navigate complex early-phase clinical development globally. With a strong focus on quality, collaboration, and scientific excellence, Southern Star Research supports trials across a range of therapeutic areas and phases. For more information, email: media@southernstarresearch.com
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ**
What are the key milestones FibroBiologics Inc. (FBLG) aims to achieve in its Phase 1/2 clinical trial for the CYWC628 treatment of diabetic foot ulcers, and how does it plan to address potential risks during this process?
How does the partnership with Southern Star Research enhance the execution and credibility of FibroBiologics Inc. (FBLG) in conducting the CYWC6trial in Australia, particularly in early-phase clinical development?
What specific safety and efficacy endpoints will FibroBiologics Inc. (FBLG) assess in the interim analysis of the CYWC628 clinical trial, and how might these results impact the future development of fibroblast therapies?
In light of FibroBiologics Inc. (FBLG) holding over 270 patents, how does the company plan to leverage its intellectual property to advance its clinical programs and secure funding for ongoing research and development efforts?
**MWN-AI FAQ is based on asking OpenAI questions about FibroBiologics Inc. (NASDAQ: FBLG).
NASDAQ: FBLG
FBLG Trading
-2.09% G/L:
$0.4161 Last:
413,818 Volume:
$0.42 Open:
